Treatment of women with BRCA mutation

References

• Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–2416.
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to Ovarian cancer. Mol Oncol. 2009;3(2):138–150.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029–2034.
   PubMed Web of Science ®Google Scholar
• Depypere H, Su Y, Dang N, et al. Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers. Eur J Cancer Prevent. 2021;30(3):195–203.
   PubMed Web of Science ®Google Scholar
• Su Y, Dang N, Depypere H, et al. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers. Eur J Cancer Prevention. 2022;10:1097.
   Google Scholar
• Michaan N, Leshno M, Cohen Y, et al. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis. Reprod Biol Endocrinol. 2021;19(1):153.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012;10:32.
   PubMed Web of Science ®Google Scholar
• Boothroyd C, Karia S, Andreadis N, et al. Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. Consensus expert panel on trial evidence (ACCEPT) group. Aust N Z J Obstet Gynaecol. 2015;55(6):523–534.
   PubMed Web of Science ®Google Scholar
• Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198.
   PubMed Web of Science ®Google Scholar
• Schrijver LH, Antoniou AC, Olsson H, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol. 2021;225(1):51.e1–51.e17.
   PubMed Web of Science ®Google Scholar
• Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–2239.
   PubMed Web of Science ®Google Scholar
• Zürcher A, Knabben L, Janka J, et al. Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Arch Gynecol Obstet. 2022 Jun 18. DOI: 10.1007/s00404-022-06640-y
   Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211–217.
   PubMed Web of Science ®Google Scholar
• Depypere H, Stanczyk F, Croubels S, et al. Breast levonorgestrel concentrations in women using a levonorgestrel-releasing intrauterine system. Contraception. 2019;100(4):299–301.
   PubMed Web of Science ®Google Scholar
• Opsomer D, Vyncke T, Depypere B, et al. Nipple reconstruction in autologous breast reconstruction after areola-sparing mastectomy. J Plast Reconstr Aesthet Surg. 2021;74(6):1223–1228.
   PubMed Web of Science ®Google Scholar
• Depypere B, Herregods S, Denolf J, et al. 20 Years of DIEAP flap breast reconstruction: a big data analysis. Sci Rep. 2019;9(1):12899.
   PubMedGoogle Scholar
• Walker JL, Powell CB, Chen LM, et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108–2120.
   PubMed Web of Science ®Google Scholar
• Walker M, Jacobson M, Sobel M. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ. 2019;12:191.
   Google Scholar
• Trémollieres F, Ceausu I, Depypere H, et al. Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas. 2017;95:65–71.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Takahashi K, Yamatani H, et al. Impact of surgical menopause on lipid and bone metabolism. Climacteric. 2011;14(4):445–452.
   PubMed Web of Science ®Google Scholar
• Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol. 2013;121(4):709–716.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–828.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083.
   PubMed Web of Science ®Google Scholar
• Maki PM, Weber MT. A research primer for studies of cognitive changes across the menopause transition. Climacteric. 2021;24(4):382–388.
   PubMed Web of Science ®Google Scholar
• Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol. 2011;121(1):163–168.
   PubMed Web of Science ®Google Scholar
• An X, Lei X, Huang R, et al. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: a single-center study and a meta-analysis of the published literature. Cancer. 2020;15(126 Suppl 16):3837–3846.
   Google Scholar
• Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in alzheimer disease – the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457–469.
   PubMed Web of Science ®Google Scholar
• Marchetti C, De Felice F, Boccia S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol. 2018;132:111–115.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term All-Cause and Cause-Specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Hampel H, Au R, Mattke S, et al. Designing the next-generation clinical care pathway for Alzheimer’s disease. Nat Aging. 2022;2(8):692–703.
   PubMedGoogle Scholar
• Depypere H, Vergallo A, Lemercier P, et al. Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer’s disease. Alzheimers Dement. 2022;2022:1–11.
   Google Scholar
• Hanley GE, McAlpine JN, Cheifetz R, et al. Selected medical interventions in women with a deleterious Brca mutation: a population-based study in British Columbia. Curr Oncol. 2019;26(1):17–23.
   Web of Science ®Google Scholar
• Fenton SE. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology. 2006;147(6):s18–s24.
   PubMed Web of Science ®Google Scholar
• Knower KC, To SQ, Leung Y-K, et al. Endocrine disruption of the epigenome: a breast cancer link. Endocr Relat Cancer. 2014;21(2):T33–T55.
   PubMed Web of Science ®Google Scholar
• Lambe M, Hsieh CC, Chan HW, et al. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Tr. 1996;38(3):305–311.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer. 2012;19(4):302–308.
   PubMed Web of Science ®Google Scholar
• Evans DG, Harkness EF, Howel S, et al. Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018;167(3):779–785.
   PubMed Web of Science ®Google Scholar
• Santucci-Pereira J, George C, Armiss D, et al. Mimicking pregnancy as a strategy for breast cancer prevention. Breast Cancer Manag. 2013;2(4):283–294.
   PubMedGoogle Scholar